EIKN (NASDAQ:EIKN) Posts Quarterly Earnings Results, Misses Expectations By $0.99 EPS

EIKN (NASDAQ:EIKN) released its quarterly earnings results on Monday. The company reported ($2.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.47) by ($0.99), FiscalAI reports.

EIKN Stock Down 0.1%

Shares of NASDAQ:EIKN opened at $9.95 on Tuesday. The firm’s 50 day simple moving average is $11.13. EIKN has a twelve month low of $7.90 and a twelve month high of $17.40.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. Cantor Fitzgerald assumed coverage on EIKN in a research note on Monday, March 2nd. They set an “overweight” rating for the company. Wall Street Zen downgraded shares of EIKN from a “hold” rating to a “sell” rating in a report on Sunday, April 5th. JPMorgan Chase & Co. assumed coverage on shares of EIKN in a report on Monday, March 2nd. They set an “overweight” rating and a $29.00 price objective for the company. Morgan Stanley assumed coverage on shares of EIKN in a report on Monday, March 2nd. They set an “overweight” rating and a $32.00 price objective for the company. Finally, Zacks Research raised shares of EIKN to a “hold” rating in a report on Friday, February 27th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, EIKN has an average rating of “Moderate Buy” and a consensus price target of $25.20.

EIKN Company Profile

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.